Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (AGIO)
NASDAQ:AGIO
Earnings Data
Report Date
Oct 30, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-1.9Last Year’s EPS
16.22Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong revenue growth for PYRUKYND, advancements in regulatory approvals, and strategic partnerships to expand global reach. However, there were also concerns about revenue variability, increased expenses, and challenges in market expansion, which could temper expectations. Overall, the highlights outweigh the lowlights, suggesting a positive sentiment.Company Guidance
Strong Revenue Growth for PYRUKYND
Second quarter net revenue was $12.5 million, marking a 45% increase compared to the second quarter of 2024 and a 44% increase from the first quarter of 2025.
Advancements in Regulatory Approvals and Trials
Agios anticipates the FDA approval of PYRUKYND for thalassemia in the U.S. by September 7. The company expects to report the Phase III RISE UP trial results for PYRUKYND in sickle cell disease by the end of the year.
Strategic Partnerships to Expand Global Reach
Agios entered agreements with Avanzanite Bioscience for Europe and NewBridge Pharmaceuticals for the GCC to commercialize PYRUKYND, enhancing its global presence.
Robust Financial Position
Agios ended the second quarter with approximately $1.3 billion in cash, cash equivalents, and marketable securities, supporting their capital allocation strategy.
Pipeline Progress
The company dosed the first patient in the Phase II trial of tebapivat for sickle cell disease and received IND clearance for AG-236, marking key advancements in their pipeline.
AGIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AGIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jul 31, 2025 | $37.54 | $37.22 | -0.85% |
May 01, 2025 | $29.69 | $30.94 | +4.21% |
Feb 13, 2025 | $32.81 | $33.30 | +1.49% |
Oct 31, 2024 | $46.30 | $44.43 | -4.04% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Agios Pharma (AGIO) report earnings?
Agios Pharma (AGIO) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).
What is Agios Pharma (AGIO) earnings time?
Agios Pharma (AGIO) earnings time is at Oct 30, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AGIO EPS forecast?
AGIO EPS forecast for the fiscal quarter 2025 (Q3) is -1.9.